Año: 2001
Journal Impact Factor (JIF): 1.1290
| Categoría | Edición | Posición | Cuartil | Tercil | Decil |
|---|---|---|---|---|---|
| PHARMACOLOGY & PHARMACY | SCIE | 113/186 | Q3 | T2 | D7 |
| ONCOLOGY | SCIE | 83/107 | Q4 | T3 | D8 |
Año: 2017
Journal Citation Indicator (JCI): 0,330
| Categoría | Posición | Cuartil | Tercil | Decil | Percentil |
|---|---|---|---|---|---|
| ONCOLOGY | 233/290 | Q4 | T3 | D9 | 19,83 |
| PHARMACOLOGY & PHARMACY | 271/336 | Q4 | T3 | D9 | 19,49 |
Año:
2011
CiteScore:
3,400
| Categoría | Posición | Cuartil | Tercil | Decil |
|---|---|---|---|---|
| Drug Discovery | 50/140 | Q2 | T2 | D4 |
| General Medicine | 1158/3161 | Q2 | T2 | D4 |
| Infectious Diseases | 85/220 | Q2 | T2 | D4 |
| Oncology | 106/273 | Q2 | T2 | D4 |
| Pharmacology (medical) | 84/214 | Q2 | T2 | D4 |
| Pharmacology | 128/304 | Q2 | T2 | D5 |
SJR año:
2001
Factor de Impacto:
0,492
| Categoría | Posición | Cuartil | Tercil | Decil |
|---|---|---|---|---|
| Medicine (miscellaneous) | 597/2823 | Q1 | T1 | D3 |
| Pharmacology (medical) | 50/165 | Q2 | T1 | D4 |
| Pharmacology | 97/269 | Q2 | T2 | D4 |
| Drug Discovery | 38/78 | Q2 | T2 | D5 |
| Infectious Diseases | 63/136 | Q2 | T2 | D5 |
| Oncology | 80/183 | Q2 | T2 | D5 |
| # | Autor | Afiliación |
|---|---|---|
| 1 | Joyanes, P | Universidad de Sevilla (Spain) |
| 2 | Pascual, A | Universidad de Sevilla (Spain) |
| 3 | Gimenez, MJ | GlaxoSmithKline plc, Spain (Spain) |
| 4 | Garcia, I | Universidad de Sevilla (Spain) |
| 5 | GlaxoSmithKline plc, Spain (Spain) | |
| 6 | Perea, E | Universidad de Sevilla (Spain) |